Jun 04, 2021 9:05am EDT Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2021 4:10pm EDT Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B
Apr 28, 2021 4:30pm EDT Immunocore Announces Upcoming Presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 12, 2021 4:30pm EDT Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
Mar 25, 2021 7:00am EDT Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
Mar 10, 2021 7:00pm EST Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Feb 19, 2021 7:00am EST Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA